REVIEW article
Front. Cardiovasc. Med.
Sec. Clinical and Translational Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1623215
ELABELA: A polypeptide with therapeutic potential in cardiovascular diseases
Provisionally accepted
- 1Department of General Medicine, The First Affiliated Hospital of Guangzhou Medical University, guangdong, China
- 2The First Affiliated Hospital of Guangzhou Medical University, guangdong, China
- 3Department of Emergency, The Eighth Affiliated Hospital of Sun Yat-sen University, shen zhen, China
- 4The Eighth Affiliated Hospital of Sun Yat-sen University, guang dong, China
- 5The Eighth Affiliated Hospital of Sun Yat-sen University, guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cardiovascular diseases (CVDs) is an increasingly common public health problem, its diagnosis and treatment still face serious challenges, it is necessary to continue to seek new approaches. Small molecule polypeptide ELABELA (ELA) has an important role in CVDs. We aims to review the role of ELA in cardiovascular development and its related mechanisms, as well as its diagnostic value and therapeutic potential in CVDs including preeclampsia, hypertension, vascular calcification, various heart diseases, ischemia reperfusion injury etc. ELA can be used as a diagnostic marker for CVDs and it can reduce oxidative stress, cell apoptosis, tissue fibrosis, vascular hypertension, promote angiogenesis and so on, and may be a diagnosis and treatment target. The review provides some strategies for the diagnosis and treatment of small molecule polypeptide ELA in CVDs and the development of targeted drugs.
Keywords: ELA, APJ, cardiovascular disease, diagnostic, Therapeutic target
Received: 05 May 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Yan, meng, yang, Huang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tong Wang, The Eighth Affiliated Hospital of Sun Yat-sen University, guangdong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.